Projects per year
Fingerprint The Fingerprint is created by mining the titles and abstracts of the person's research outputs and projects/funding awards to create an index of weighted terms from discipline-specific thesauri.
- 2 Similar Profiles
Renal Cell Carcinoma
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Survival
Medicine & Life Sciences
Neoplasms
Medicine & Life Sciences
Protein-Tyrosine Kinases
Medicine & Life Sciences
Disease-Free Survival
Medicine & Life Sciences
Cost-Benefit Analysis
Medicine & Life Sciences
Breast Neoplasms
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Projects 2017 2019
- 7 Finished
Cost effectivness of multiplexed predictive tumor mutational burden in lung cancer using real world data
1/1/19 → 12/31/19
Project: Research project
Tumor Burden
Lung Neoplasms
Costs and Cost Analysis
Feasibility study to identify non-small cell lung cancer patients with EGFR mutation within the Oncology Research Information Exchange Network (ORIEN)
8/1/18 → 1/31/19
Project: Research project
Information Services
Feasibility Studies
Non-Small Cell Lung Carcinoma
Mutation
Research
Novel drugs targeting metabolic plasticity for breast ca
Mereddy, V. R., Potter, D. A. & Stenehjem, D. D.
Whiteside Inst. for Clinical Research
2/1/18 → 12/31/19
Project: Research project
Drug Delivery Systems
Breast Neoplasms
Therapeutics
Systematic review
Research Output 2009 2019
Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center
Willis, C., Menon, J., Unni, S., Au, T., Yoo, M., Biskupiak, J., Brixner, D., Ndife, B., Joseph, G., Bonifacio, G., Stein, E., Tantravahi, S., Shami, P. J., Kovacsovics, T. & Stenehjem, D., Dec 2019, In : Leukemia research. 87, 106262.Research output: Contribution to journal › Article
4'-N-benzoylstaurosporine
Acute Myeloid Leukemia
Protein-Tyrosine Kinases
Economics
Neoplasms
Dynamic dosing of romiplostim in patients with immune thrombocytopenia purpura: Two case reports
Gilreath, J. A., Wei, M., Paul, S., Parker, C. J., Stenehjem, D. D. & Rodgers, G. M., Apr 1 2019, In : Journal of Oncology Pharmacy Practice. 25, 3, p. 719-723 5 p.Research output: Contribution to journal › Article
Purpura
Idiopathic Thrombocytopenic Purpura
Platelet Count
Thrombopoietin Receptors
Patient Harm
1
Citation
(Scopus)
Evolution of the genomic landscape of circulating tumor DNA (ctDNA) in metastatic prostate cancer over treatment and time
Hahn, A. W., Stenehjem, D. D., Nussenzveig, R., Carroll, E., Bailey, E., Batten, J., Maughan, B. L. & Agarwal, N., Jan 1 2019, In : Cancer Treatment and Research Communications. 19, 100120.Research output: Contribution to journal › Article
Prostatic Neoplasms
DNA
Neoplasms
Therapeutics
Biopsy
1
Citation
(Scopus)
Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center
Stenehjem, D. D., Au, T. H., Ngorsuraches, S., Ma, J., Bauer, H., Wanishayakorn, T., Nelson, R. S., Pfeiffer, C. M., Schwartz, J., Korytowsky, B., Oderda, G. & Brixner, D. I., Dec 1 2019, In : Melanoma research. 29, 6, p. 626-634 9 p.Research output: Contribution to journal › Article
Open Access
Patient Preference
Melanoma
Neoplasms
Immunotherapy
Therapeutics
1
Citation
(Scopus)
Phase I/II study of everolimus combined with mFOLFOX-6 and bevacizumab for first–line treatment of metastatic colorectal cancer
Weldon Gilcrease, G., Stenehjem, D. D., Wade, M. L., Weis, J., McGregor, K., Whisenant, J., Boucher, K. M., Thorne, K., Orgain, N., Garrido-Laguna, I. & Sharma, S., Jun 15 2019, In : Investigational New Drugs. 37, 3, p. 482-489 8 p.Research output: Contribution to journal › Article
Colorectal Neoplasms
Maximum Tolerated Dose
Stomatitis
Hypokalemia
Therapeutics